Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY-NCInternational journal of nanomedicine

Zinc Hexacyanoferrate Nanoenzymes Attenuate Neuroinflammation After Spinal Cord Injury by Modulating Mitochondrial Function and Microglial Polarization.

  1. 1School of Rehabilitation Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, People's Republic of China.
  2. 2Department of Orthopaedic Rehabilitation, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121000, People's Republic of China.

Abstract

Background

Secondary pathology after acute spinal cord injury (SCI) is driven by pathological iron accumulation, reactive oxygen species (ROS) overproduction, and mitochondrial failure, which together sustain chronic neuroinflammation. Methylprednisolone (MP), the most widely used ROS-scavenging agent for acute SCI, provides limited clinical benefit and carries considerable side effects. To address this, we engineered zinc hexacyanoferrate nanoenzymes (ZnHPB) that chelate excess ferrous ions while displaying intrinsic SOD- and CAT-like activities, attenuating oxidative injury at its source rather than merely suppressing downstream inflammation. The defining feature of ZnHPB is a Fe(II)-driven self-reinforcing antioxidant loop in which captured ferrous species are converted into mixed-valence Prussian-blue phases, breaking the Fenton cascade that underpins iron- and ROS-driven secondary injury.Methods

ZnHPB was prepared by polyvinylpyrrolidone-directed self-assembly and characterized for physicochemical and enzyme-mimetic properties. In vitro efficacy was evaluated in H₂O₂-challenged BV2 microglia in parallel with MP. C57BL/6 mice subjected to T8-T9 contusion SCI received ZnHPB (5 mg/kg, i.p.) under preventive or post-injury dosing regimens for 28 days, with a 60-day safety assessment. Outcome measures included cell viability, ROS levels, mitochondrial bioenergetics (ECAR/OCR), microglial phenotypic markers, plasma injury biomarkers, and histopathology of the lesion.Results

In H₂O₂-challenged BV2 cells, ZnHPB improved viability more effectively than MP, with associated reductions in intracellular ROS, partial restoration of mitochondrial OXPHOS capacity, and alleviation of ferroptosis-related transcriptional signatures (GPX4, ACSL4, COX2). In SCI mice, ZnHPB preserved 86.71% (preventive) and 74.06% (post-injury) of white matter at the lesion epicenter and restored plasma CK, AST, and LDH toward physiological levels. Microglial phenotypic markers shifted from an M1-associated toward an M2-associated phenotype. No visceral toxicity was observed over 60 days.Conclusion

By integrating ferrous-ion sequestration with ROS elimination and mitochondrial support, ZnHPB interrupts the self-perpetuating loop of oxidative stress and neuroinflammation that characterizes secondary SCI pathology. Under the conditions tested, ZnHPB compared favorably with MP across multiple preclinical readouts, supporting further mechanistic and translational evaluation.

Related

  1. Astragalus Polysaccharide Hydrogel Promotes Diabetic Wound Healing by Modulating Macrophage Polarization and the Immune Microenvironment
    Leizi Chai, Peiji Lu, Wenhui Liu +5
    Journal of Inflammation ResearchPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMCEurope PMC
  2. Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease
    S. Upadhyay, L. Zhang, B. Kaur +3
    bioRxivPreprintAll rights reservedFull textPharmacology & toxicologybioRxivPMC
  3. Sympathetic Modulation of Neuroinflammation by Reserpine Improves Neurogenesis in ICR Mice with Traumatic Brain Injury
    Natalia Ermakova, Edgar Pan, Victoria Skurikhina +5
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Paclitaxel-induced neuroinflammation after systemic administration in male and female mice
    Martial Caillaud, Yogesh Rakholia, Lauren Soleo +6
    The Journal of PainPeer-reviewedLicence not stated4 citedOncologyHAL
  5. Epigenetic Viral Mimicry in Neuroinflammation: Retrotransposons, cGAS–STING and Microglial Hysteresis
    Sorin Ioan Tudorache, Valentin Titus Grigorean, Adrian Vasile Dumitru +5
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{liu2026zinc,
  title = {{Zinc Hexacyanoferrate Nanoenzymes Attenuate Neuroinflammation After Spinal Cord Injury by Modulating Mitochondrial Function and Microglial Polarization.}},
  author = {Ruifang Liu and Yu Luo and Sen Lin},
  journal = {International journal of nanomedicine},
  year = {2026},
  month = oct,
  doi = {10.2147/ijn.s638767},
  url = {https://europepmc.org/article/MED/42903876},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Zinc Hexacyanoferrate Nanoenzymes Attenuate Neuroinflammation After Spinal Cord Injury by Modulating Mitochondrial Function and Microglial Polarization.
AU  - Ruifang Liu
AU  - Yu Luo
AU  - Sen Lin
PY  - 2026
DA  - 2026/10/16
JO  - International journal of nanomedicine
DO  - 10.2147/ijn.s638767
UR  - https://europepmc.org/article/MED/42903876
AB  - Background  Secondary pathology after acute spinal cord injury (SCI) is driven by pathological iron accumulation, reactive oxygen species (ROS) overproduction, and mitochondrial failure, which together sustain chronic neuroinflammation. Methylprednisolone (MP), the most widely used ROS-scavenging agent for acute SCI, provides limited clinical benefit and carries considerable side effects. To address this, we engineered zinc hexacyanoferrate nanoenzymes (ZnHPB) that chelate excess ferrous ions while displaying intrinsic SOD- and CAT-like activities, attenuating oxidative injury at its source rather than merely suppressing downstream inflammation. The defining feature of ZnHPB is a Fe(II)-driven self-reinforcing antioxidant loop in which captured ferrous species are converted into mixed-valence Prussian-blue phases, breaking the Fenton cascade that underpins iron- and ROS-driven secondary injury.Methods  ZnHPB was prepared by polyvinylpyrrolidone-directed self-assembly and characterized for physicochemical and enzyme-mimetic properties. In vitro efficacy was evaluated in H₂O₂-challenged BV2 microglia in parallel with MP. C57BL/6 mice subjected to T8-T9 contusion SCI received ZnHPB (5 mg/kg, i.p.) under preventive or post-injury dosing regimens for 28 days, with a 60-day safety assessment. Outcome measures included cell viability, ROS levels, mitochondrial bioenergetics (ECAR/OCR), microglial phenotypic markers, plasma injury biomarkers, and histopathology of the lesion.Results  In H₂O₂-challenged BV2 cells, ZnHPB improved viability more effectively than MP, with associated reductions in intracellular ROS, partial restoration of mitochondrial OXPHOS capacity, and alleviation of ferroptosis-related transcriptional signatures (GPX4, ACSL4, COX2). In SCI mice, ZnHPB preserved 86.71% (preventive) and 74.06% (post-injury) of white matter at the lesion epicenter and restored plasma CK, AST, and LDH toward physiological levels. Microglial phenotypic markers shifted from an M1-associated toward an M2-associated phenotype. No visceral toxicity was observed over 60 days.Conclusion  By integrating ferrous-ion sequestration with ROS elimination and mitochondrial support, ZnHPB interrupts the self-perpetuating loop of oxidative stress and neuroinflammation that characterizes secondary SCI pathology. Under the conditions tested, ZnHPB compared favorably with MP across multiple preclinical readouts, supporting further mechanistic and translational evaluation.
SN  - 1176-9114
SN  - 1178-2013
ER  -